Miranda Schmalfuhs

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, identifies the main factors contributing to closures of pharmacies big and small and some potential long-term consequences for public health if they continue.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, speaks about the specific challenges that pharmacy deserts becoming a national issue presents for rural and underserved areas. Plus a discussion of which alternative solutions can help ensure continued access to medications for all.

David Minkin, President & GM at epocrates, offers his insights into the importance of trust, first-party data, and strategic partnerships in ensuring successful marketing campaigns.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, shares advice for investors and financiers who are considering entering the weight-loss medication market.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, talks about what steps companies developing weight-loss medications should take to ensure responsible and ethical practices.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, and what needs to be done for GLP-1s to be covered.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses the top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Brice Challamel, Vice President, AI Products & Platforms, Moderna, talks about how Moderna will leverage its collaboration with OpenAI to accelerate the development and launch of its upcoming mRNA medicines

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Brice Challamel, Vice President, AI Products & Platforms, Moderna, discusses how Moderna is ensuring responsible and ethical use of AI technology within its operations.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Brice Challamel, Vice President, AI Products & Platforms, Moderna, speaks about challenges Moderna faced integrating generative AI,like mChat and GPTs, into its various departments and how they overcame them.